JoVE Logo

Zaloguj się

Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.

W tym Artykule

  • Podsumowanie
  • Streszczenie
  • Wprowadzenie
  • Protokół
  • Wyniki
  • Dyskusje
  • Materiały
  • Odniesienia
  • Przedruki i uprawnienia

Podsumowanie

This article describes the isolation of mouse aortic valve cells by a two-step collagenase procedure. Isolated mouse valve cells are important for performing different assays, such as this in vitro calcification assay, and for investigating the molecular pathways leading to aortic valve mineralization.

Streszczenie

The calcification of aortic valve cells is the hallmark of aortic stenosis and is associated with valve cusp fibrosis. Valve interstitial cells (VICs) play an important role in the calcification process in aortic stenosis through the activation of their dedifferentiation program to osteoblast-like cells. Mouse VICs are a good in vitro tool for the elucidation of the signaling pathways driving the mineralization of the aortic valve cell. The method described herein, successfully used by these authors, explains how to obtain freshly isolated cells. A two-step collagenase procedure was performed with 1 mg/mL and 4.5 mg/mL. The first step is crucial to remove the endothelial cell layer and avoid any contamination. The second collagenase incubation is to facilitate the migration of VICs from the tissue to the plate. In addition, an immunofluorescence staining procedure for the phenotype characterization of the isolated mouse valve cells is discussed. Furthermore, the calcification assay was performed in vitro by using the calcium reagent measurement procedure and alizarin red staining. The use of mouse valve cell primary culture is essential for testing new pharmacological targets to inhibit cell mineralization in vitro.

Wprowadzenie

Calcified aortic valve disease (CAVD) is the most prevalent valvular heart disease in western populations, affecting nearly 2.5% of elderly individuals over 65 years of age1. CAVD affects over six million Americans and is associated with changes in the mechanical properties of the leaflets that impair normal blood flow-through1,2. Currently, there is no pharmacological treatment to stop the progression of the disease or to activate mineral regression. The only effective therapy to treat CAVD is aortic valve replacement by surgery or transcatheter aortic valve replacement3. It is therefore imperative to investigate the molecular mechanisms leading to valve mineralization to identify new pharmacological targets. Indeed, non-treated aortic stenosis has several adverse consequences such as left ventricle dysfunction and heart failure4.

The aortic valve consists of three layers known as fibrosa, spongiosa, and ventricularis, which contain VICs as the predominant cell type5. The fibrosa and the ventricularis are covered by a layer of vascular endothelial cells (VECs)5. The VECs regulate the permeability of inflammatory cells as well as paracrine signals. Increased mechanical stress may affect the integrity of the VECs and disturb the homeostasis of the aortic valve, leading to inflammatory cell invasion6. Scanning electron microscopy analyses showed disrupted endothelium in a human calcified aortic valve7.

Histological analyses of calcified tissue reveal the presence of osteoblasts and osteoclasts. Furthermore, osteogenic differentiation of VICs was observed both in vitro and in human valve tissue8. This process is mainly orchestrated by the Runt-related transcription factor 2 (Runx2) and the bone morphogenetic proteins (BMPs)8,9.

Protokół

NOTE: All animal procedures described here have been approved by Icahn School of Medicine at Mount Sinai institutional core and use committee.

1. Preparation before valve cell isolation from adult mice

  1. Clean and sterilize all the surgical instruments shown in Figure 1A by using 70% v/v ethanol and subsequently autoclaving them for 30 min. clean the surgical workspace with 70% ethanol.
  2. Add 500 µL of penicillin-streptomycin to 50 mL of 10 mm HEPES. Prepare an aliquot of 50 mL of 1x phosphate-buffered saline (PBS). Keep the solutions on ice.
  3. Prepare 1 mg/mL and 4.5 mg/mL collagenase solutions, and use 5 mL of each solution in 15 mL tubes to perform the entire procedure. To prepare 5 mL of 1 mg/mL collagenase, mix 5 mg of collagenase with 2.5 mL of Dulbecco's Modified Eagle Medium (DMEM, fetal bovine serum (FBS)-free) and 2.5 mL of 10 mM HEPES supplemented with antibiotics (1% penicillin-streptomycin from step 1.2). Filter the solutions through a 0.22 µm filter to remove any contamination.
    NOTE: Keep the solutions on ice to protect the enzymes.
  4. Warm the DMEM solution to 37 °C before use in all the steps described below. Prepare complete medium by supplementing DMEM with 1% penicillin-streptomycin, 1% sodium pyruvate, 5 mL of 200 mM L-glutamine, 1 mL of mycoplasma elimination reagent (see the Table of Materials), and 10% FBS.

2. Isolation of valve cells

  1. To obtain 106 cells for the experiment, use five 8-week-old mice (minimum of three). Place the mouse in an induction chamber along with a small piece of tissue paper soaked with 1 mL of isoflurane, but do not allow contact with the tissue. To confirm that the animal is fully anesthetized; check for toe pinch reflex, and then euthanize the mouse by cervical dislocation. Use isoflurane to alleviate any pain prior to the cervical dislocation as the procedure described below is terminal.
  2. Place the mouse on a dissecting platform, and fix the paws with cannulas to hold it in place. Clean the chest and the abdomen with ethanol; open the abdomen and the chest with scissors. With small surgical scissors, cut between the left atrium and the left ventricle to exsanguinate the mouse. Perfuse the heart with 10 mL of cold 1x PBS to remove blood from the heart.
  3. Cut the heart, and keep 3 mm from the ascending aorta as shown in Figure 1B. Dissect the aortic valve under a stereomicroscope. Cut the heart horizontally in the middle of the ventricles (Figure 1C). Cut the left ventricle toward the aorta, and carefully dissect the aortic valve (Figure 1D-F). Pool the valves together in a small 35 mm tissue culture dish.
  4. Wash the isolated valves in a 75 mm cell culture dish with 5 mL of cold HEPES (10 mM) supplemented with antibiotics (1% penicillin-streptomycin) to remove blood (Figure 2). Prepare two 15 mL tubes of collagenase 1 mg/mL and 4.5 mg/mL as described above in step 1.3.
    NOTE: After the dissection, manipulate the isolated valves in a sterile biosafety hood to minimize contamination.
  5. Incubate the valves in collagenase type I (1 mg/mL) for 30 min at 37 °C with continuous shaking (Figure 2). Centrifuge the tube for 5 min at 150 × g, wash the pellet once with 2 mL of HEPES (10 mM), and vortex for 30 s at high speed. Pour the contents of this tube into a 35 mm culture dish, and carefully transfer the fragments of tissue using thin tweezers into a new tube.
    NOTE: At this stage, the VICs are still not dissociated from the tissue, and the pellet contains pieces of tissue. To avoid contamination with endothelial cells, do not centrifuge after vortexing in step 2.5.
  6. Incubate the pellet in a 15 mL tube with 5 mL of collagenase type I (4.5 mg/mL) at 37 °C under continuous agitation for 35 min. Re-suspend the cells with a 1 mL pipette to separate the cells, and centrifuge at 150 × g for 5 min at 4 °C.
  7. Discard the supernatant, and re-suspend the pellet in 2 mL of complete DMEM. Centrifuge at 150 × g for 5 min at 4 °C. Repeat this step twice to clean the cells.
    NOTE: The pellet will still have some tissue fragments.
  8. Re-suspend the pellet in 1 mL of complete medium, and plate the cells in one well of a 6-well cell culture dish in a minimum amount of medium to facilitate their attachment to the culture dish. Leave the cells, undisturbed, in a 37 °C incubator with 5% carbon dioxide.
  9. After 3 days, check the cells under the microscope to verify good growth close to the tissue debris. Once 1,000 cells are visible under the microscope, carefully remove the tissue debris with autoclaved tweezers, and change the medium.
    NOTE: The plate should not be disturbed; if the required number of cells are not observed, place the cell culture dish back in the incubator for another 2 days.
  10. When the cells are 70% confluent (2.5 × 105), trypsinize and then transfer them to a 75 mm tissue culture dish.

3. Analysis of cell identity and morphology

NOTE: Immunofluorescence staining was used to study cell morphology and endothelial cell contamination.

  1. Clean the hood with 70% v/v/ ethanol. Place sterile coverslips (22 mm x 22 mm) in 6-well plates.
    NOTE: To sterilize the coverslips, wash them with 70% ethanol, and keep them in the hood overnight under ultraviolet light.
  2. Seed 100,000 cells per well in a 6-well plate. After 24 h, wash the cells twice in 1x PBS, and fix them in 4% paraformaldehyde (PFA) for 20 min. Wash the cells again twice with 1x PBS.
    NOTE: At this point, the cells could be kept in PBS at 4 °C until the start of the staining procedure.
  3. To verify the purity of the VICs, use alpha-smooth muscle actin (αSMA), vimentin, and cluster of differentiation 31 (CD31) to detect contamination with VECs.
  4. Prepare an aliquot of blocking buffer by mixing 500 µL of normal serum (the same species as the secondary antibody), 9.5 mL of 1x PBS, and 30 µL of Triton X-100. Incubate the cells in 2 mL of the blocking buffer for 1 h.
  5. Prepare the antibody dilution buffer containing 30 µL of Triton X-100, 10 mL of 1x PBS, and 0.1 g of bovine serum albumin (BSA).
  6. Take an empty tips box, fill half of the box with water to create a humid chamber. Cover the tip holder with a wet tissue and then with a sheet of parafilm.
  7. Take 1 µL of the primary antibody, and mix it with 100 µL of the dilution buffer prepared in step 3.5. Place 50 µL of the diluted antibody on the parafilm. Take the coverslips from the wells, flip them over, and place them on the top of the drops of antibody; incubate the cells overnight with the antibody.
  8. Add 1 mL of PBS in the 6-well plate. Carefully take out the coverslip from the parafilm, flip it over, and place it in the well. Wash the cells with a continuous gentle agitation for 5 min. Replace the PBS with fresh PBS; wash the cells 3 times.
  9. Incubate the cells with the diluted secondary antibody (1/500) (Alexa-488, Alexa-555) for 1 h. Add 1 µL of the secondary antibody to 500 µL of the antibody dilution buffer (prepared in step 3.5). Cover the plate with aluminum foil. Wash the cells 3 times with 1 mL of 1x PBS with continuous agitation.
  10. Mount the coverslips with 50 µL of 4′,6-diamidino-2-phenylindole (DAPI)-mounting medium, and observe the cells under the microscope to analyze the morphology of cells and VEC contamination.

4. In vitro calcification assay

  1. Clean the hood with 70% ethanol, warm the DMEM medium to 37 °C.
  2. Seed 100,000 cells/condition into 6-well plates in complete DMEM, and culture for 24 h at 37 °C.
  3. Prepare the calcifying medium by mixing 2 mM of NaH2PO4, 10-7 M insulin, and 50 µg/mL ascorbic acid in DMEM with 5% FBS. For 93 mL of DMEM, add 5 mL of FBS, 1 mL of antibiotics (final concentration 1%), 1 mL of sodium pyruvate (100 mM), 27.5 mg of NaH2PO4, 5.8 µL of insulin, and 5 mg of ascorbic acid.
    NOTE: Filter the solution using a 0.22 µm filter before use.
  4. After 24 h, replace the supernatant medium with the calcifying medium. Incubate the cells for 7 days at 37 °C. On the 3rd day, replace with fresh calcifying medium, and place the plate back in the incubator to complete the 7 days of treatment.
  5. After 7 days, remove the medium, and wash the cells twice with 2 mL of 1x PBS. Incubate the cells in 1 mL of 0.6 N hydrochloric acid (HCl) for 24 h at 37 °C. Collect the HCl in a 1.5 mL tube, and evaporate it in a rotary evaporator. Re-suspend the contents of all the tubes in 60 µL of HCl.
    NOTE: The drying procedure is important to concentrate the solution and to have the same volume for each condition.
  6. Use a 96-well plate to measure calcium concentration by using Arsenazo III reagent, available in a ready-to-use kit (see the Table of Materials for more details).
  7. Prepare a calcium standard solution of 10 mg/dL concentration. Weigh 10 mg of calcium hydroxide (Ca(OH)2) and dissolve in 100 mL of distilled water.
  8. In a clear 96 well plate, pipet 2 µL of blank solution (HCl, 0.6 N), the standard solution, the sample per well (10 mg/dL), and the samples. Perform the experiment in triplicate to verify the pipetting variability. Add 200 µL of the reagent for each condition.
    NOTE: Samples above 15 mg/dL should be diluted 1:1 with saline, re-assayed, and the result multiplied by two.
  9. Incubate the reaction for 15 min at room temperature.
    NOTE: The reaction is stable for 60 min.
  10. Read and record the absorbance of the plate at 650 nm. Use the following formula to calculate the amount of calcium in the samples:
    Calcium (mg/mL) = (Absorbance of sample/absorbance of standard) × Concentration of standard

Wyniki

As murine aortic valves are typically 1 mm in diameter, at least three valves must be pooled to collect a million viable cells for different experimental procedures. The different steps of the VIC isolation process are shown in Figure 1 and Figure 2. As it is difficult to manually scrape the valve tissue, it is preferable to use shear stress created by vortexing to remove the VECs. Indeed, the CD31 immunofluorescence staining results showed the absence of endoth...

Dyskusje

This article presents a detailed protocol of mouse valve cell isolation for primary culture. Three aortic valves from 8-week-old mice were pooled to obtain an adequate number of cells. In addition, this protocol describes the characterization of VIC phenotype and the in vitro mineralization assay. The method was adapted from the previously described protocol from Mathieu et al.7.

During the isolation of aortic valves, care must be taken to avoid all so...

Materiały

NameCompanyCatalog NumberComments
3 mm cutting edge scissorsF.S.T15000-00
Anti-alpha smooth muscle Actin antibodyabcam
Anti-mouse, Alexa Fluor 488 conjugateCell Signaling4412
Arsenazo-III reagent setPOINT SCIENTIFICC7529-500a Kit to measure the concentration of calcium
Bonn ScissorsF.S.T14184-09
Calcium hydroxideSIGMA -Aldrich 3121931219
CD31Novusbio
Collagenase type I  (125 units/mg)Thermofisher Scientific17018029
DMEMTthermofisher11965092
Extra fine graefe forcepsF.S.T11150-10
FBSGibco 16000044
Fine forcepsF.S.T Dumont
HClSIGMA-ALDRICHH1758
HEPES 1 M solutionSTEMCELLS TECHNOLOGIES
L-Glutamine 100xThermofisher ScientificA2916801
MycozapLanzaVZA-2011Mycoplasma elimination reagent
PBS 10xSIGMA-ALDRICH
penecillin streptomycin 100xThermofisher Scientific10378016
Sodium Pyruvate 100 mMThermofisher Scientific11360070
Standard pattern forceps F.S.T11000-12
Surgical Scissors - Sharp-BluntF.S.T14008-14
Trypsin 0.05%Thermofisher Scientific25300054
Vimentinabcam

Odniesienia

  1. Rostagno, C. Heart valve disease in elderly. World Journal of Cardiology. 11 (2), 71-83 (2019).
  2. Stewart, B. F., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. Journal of the American College of Cardiology. 29 (3), 630-634 (1997).
  3. Marquis-Gravel, G., Redfors, B., Leon, M. B., Généreux, P. Medical treatment of aortic stenosis. Circulation. 134 (22), 1766-1784 (2016).
  4. Spitzer, E., et al. Aortic stenosis and heart failure: disease ascertainment and statistical considerations for clinical trials. Cardiac Failure Review. 5 (2), 99-105 (2019).
  5. Hinton, R. B., Yutzey, K. E. Heart valve structure and function in development and disease. Annual Review of Physiology. 73, 29-46 (2011).
  6. Simionescu, D. T., Chen, J., Jaeggli, M., Wang, B., Liao, J. Form follows function: advances in trilayered structure replication for aortic heart valve tissue engineering. Journal of Healthcare Engineering. 3 (2), 179-202 (2012).
  7. Bouchareb, R., et al. Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis. European Heart Journal. 40 (17), 1362-1373 (2019).
  8. Rutkovskiy, A., et al. Valve interstitial cells: the key to understanding the pathophysiology of heart valve calcification. Journal of the American Heart Association. 6 (9), (2017).
  9. Bosse, Y., Mathieu, P., Pibarot, P. Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis. Journal of the American College of Cardiology. 51 (14), 1327-1336 (2008).
  10. Drexler, H. G., Uphoff, C. C. Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology. 39 (2), 75-90 (2002).
  11. Richards, J., et al. Side-specific endothelial-dependent regulation of aortic valve calcification: interplay of hemodynamics and nitric oxide signaling. American Journal of Pathology. 182 (5), 1922-1931 (2013).
  12. Bouchareb, R., et al. Mechanical strain induces the production of spheroid mineralized microparticles in the aortic valve through a RhoA/ROCK-dependent mechanism. Journal of Molecular and Cellular Cardiology. 67, 49-59 (2014).
  13. Lerman, D. A., Prasad, S., Alotti, N. Calcific aortic valve disease: molecular mechanisms and therapeutic approaches. European Cardiology. 10 (2), 108-112 (2015).
  14. Janssen, J. W., Helbing, A. R. Arsenazo III: an improvement of the routine calcium determination in serum. European Journal of Clinical Chemistry and Clinical Biochemistry. 29 (3), 197-201 (1991).
  15. Ortlepp, J. R., et al. Lower serum calcium levels are associated with greater calcium hydroxyapatite deposition in native aortic valves of male patients with severe calcific aortic stenosis. Journal of Heart Valve Disease. 15 (4), 502-508 (2006).

Przedruki i uprawnienia

Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE

Zapytaj o uprawnienia

Przeglądaj więcej artyków

Mouse Valve CellsAortic Valve CalcificationTransgenic MiceIsolation ProtocolTwo step DigestionSurgical Instruments SterilizationCold PBS PerfusionCollagenase Type One IncubationCell CultureCentrifugationTissue Culture DishDMEM Plating

This article has been published

Video Coming Soon

JoVE Logo

Prywatność

Warunki Korzystania

Zasady

Badania

Edukacja

O JoVE

Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone